Abstract
Pharmaceutical nanocarriers are increasingly recognized for their potential in overcoming the blood-brain barrier (BBB) to enable targeted drug delivery to the brain. These carriers, including liposomes, polymeric nanoparticles, and solid lipid nanoparticles, have revolutionized the field of brain-targeted drug delivery, offering enhanced bioavailability, controlled release, and reduced side effects. The ability to encapsulate both hydrophobic and hydrophilic drugs in nanocarriers has opened new avenues for treating neurological disorders such as Alzheimer's disease, Parkinson's disease, and brain tumors. This article reviews the mechanisms, advantages, and challenges associated with pharmaceutical nanocarriers in brain drug delivery, focusing on the various approaches being developed to improve the efficiency of these systems.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.